XML 43 R36.htm IDEA: XBRL DOCUMENT v3.25.3
Revenue - Schedule of Disaggregated Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Disaggregation Of Revenue [Line Items]        
Revenue $ 93,973 $ 46,435 $ 205,295 $ 131,498
MRD Revenue        
Disaggregation Of Revenue [Line Items]        
Revenue 56,788 37,470 150,447 105,380
MRD Revenue | Service Revenue        
Disaggregation Of Revenue [Line Items]        
Revenue 50,288 32,470 133,947 92,880
MRD Revenue | Regulatory Milestone Revenue        
Disaggregation Of Revenue [Line Items]        
Revenue 6,500 5,000 16,500 12,500
Immune Medicine Revenue        
Disaggregation Of Revenue [Line Items]        
Revenue 37,185 8,965 54,848 26,118
Immune Medicine Revenue | Service Revenue        
Disaggregation Of Revenue [Line Items]        
Revenue 3,443 5,453 13,566 16,160
Immune Medicine Revenue | Collaboration Revenue        
Disaggregation Of Revenue [Line Items]        
Revenue [1] $ 33,742 $ 3,512 $ 41,282 $ 9,958
[1] On August 13, 2025, the Genentech Agreement was terminated, with termination effective February 9, 2026. See “Genentech Collaboration Agreement” below for more information regarding the resulting impact on revenue recognized during the three and nine months ended September 30, 2025.